Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with celiac disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion.

Celiac Disease

Affecting an estimated 2.4 million Americans, celiac disease is associated with acute gastrointestinal symptoms, malnutrition, and increased mortality. The disease is currently treated by a gluten-free diet, which is costly and challenging to maintain strict compliance. Despite adhering to a gluten-free diet, many patients continue to report persistent symptoms.


PvP Biologics is developing an oral enzyme, called KumaMax, for the treatment of celiac disease. The technology was invented at the Institute for Protein Design at University of Washington and is exclusively in-licensed by PvP Biologics.


Related Link